U.S. Capital Wealth Advisors LLC Has $7.14 Million Holdings in Eli Lilly and Company (NYSE:LLY)

U.S. Capital Wealth Advisors LLC trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 57.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 8,645 shares of the company's stock after selling 11,531 shares during the period. U.S. Capital Wealth Advisors LLC's holdings in Eli Lilly and Company were worth $7,140,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Brass Tax Wealth Management Inc. raised its holdings in shares of Eli Lilly and Company by 0.3% during the first quarter. Brass Tax Wealth Management Inc. now owns 8,330 shares of the company's stock worth $6,880,000 after purchasing an additional 26 shares during the period. Security National Bank of SO Dak raised its holdings in shares of Eli Lilly and Company by 14.5% during the first quarter. Security National Bank of SO Dak now owns 916 shares of the company's stock worth $757,000 after purchasing an additional 116 shares during the period. Liberty Square Wealth Partners LLC raised its holdings in shares of Eli Lilly and Company by 3.1% during the first quarter. Liberty Square Wealth Partners LLC now owns 726 shares of the company's stock worth $600,000 after purchasing an additional 22 shares during the period. Callan Capital LLC raised its holdings in shares of Eli Lilly and Company by 15.7% during the first quarter. Callan Capital LLC now owns 4,745 shares of the company's stock worth $3,919,000 after purchasing an additional 645 shares during the period. Finally, TD Private Client Wealth LLC raised its holdings in shares of Eli Lilly and Company by 3.1% during the first quarter. TD Private Client Wealth LLC now owns 5,607 shares of the company's stock worth $4,631,000 after purchasing an additional 169 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY traded up $6.72 during trading hours on Thursday, hitting $793.64. 2,006,498 shares of the company's stock traded hands, compared to its average volume of 3,662,090. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The company's fifty day simple moving average is $767.12 and its two-hundred day simple moving average is $800.05. The company has a market cap of $752.16 billion, a price-to-earnings ratio of 64.54, a price-to-earnings-growth ratio of 1.14 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The business had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. During the same quarter last year, the business posted $2.58 EPS. The business's revenue for the quarter was up 45.2% on a year-over-year basis. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be issued a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.76%. Eli Lilly and Company's dividend payout ratio is currently 48.82%.

Analyst Ratings Changes

A number of research firms recently weighed in on LLY. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their price objective for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. Morgan Stanley reaffirmed an "overweight" rating and issued a $1,135.00 price objective (up previously from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday. Cantor Fitzgerald began coverage on shares of Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price objective on the stock. HSBC cut shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and dropped their price objective for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. Finally, Erste Group Bank cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $1,012.22.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.